EVITALIN ONLINE CLINIC
GLP-1 Agonists in Clinical Practice: A Prescriber’s Guide
A clinical deep dive into GLP-1 and tirzepatide therapy covering mechanism of action, dosing protocols, side effect management, contraindications, emerging indications, and strategies for building a comprehensive weight loss practice.
Free Access – 48 Minutes
Full presentation + Q&A
Click to watch video
WHAT YOU’LL LEARN
Clinical Knowledge You Can Apply Immediately
A comprehensive clinical education session covering the science, practice, and business of GLP-1 therapy.
Mechanism of Action
How GLP-1 and dual-acting GIP/GLP-1 agonists work across the pancreas, GI tract, adipose tissue, and brain to drive metabolic improvement.
Clinical Indications
FDA-approved uses for type 2 diabetes, obesity, and obstructive sleep apnea, plus emerging evidence for CKD, cardiovascular disease, MASH, and PAD.
Dosing Protocols
Start-low-go-slow titration strategies for semaglutide and tirzepatide, subcutaneous vs. oral formulations, and minimum effective dose philosophy.
Side Effect Management
Practical approaches to GI side effects (nausea, sulfur burps, acid reflux), when to switch medications, and managing patient expectations.
Patient Education Protocols
Structuring monthly monitoring visits, nutrition guidance (25g protein per meal), injection training, and documentation for litigation protection.
Building a Weight Loss Practice
How to structure a comprehensive program beyond medication, including membership models, telehealth, compounding pharmacy selection, and pricing considerations.
Key Data Points By the Numbers
15-20%
Total Body weight loss is achievable over 6 to 12 months with GLP-1 and dual-acting agonists under proper clinical supervision.
20%
Reduction in major adverse cardiovascular events demonstrated with semaglutide in the SELECT trial
62%
Resolution rate for metabolic dysfunction-associated steatohepatitis with fibrosis improvement in the ESSENCE trial
2-4%
Expected weight loss in the first month of therapy provides a useful early indicator of patient response
Dr. Mahnaz Qayyum
Physician, Concierge Practice
Dr. Qayyum is a concierge physician with extensive experience prescribing GLP-1 agonists and tirzepatide for weight management and metabolic health. His practice focuses on personalized patient care with monthly monitoring visits, comprehensive nutrition and exercise counseling, and evidence-based prescribing protocols. In this presentation, he shares practical clinical insights drawn from real-world patient outcomes.
Live Q&A Highlights
Questions From Providers Like You
Can cancer patients use GLP-1 agonists?
Semaglutide or tirzepatide first?
What baseline labs are needed?
THIS PRESENTATION IS
Powered by Pharmalabs
Evitalin partners with PharmaLabs, a 503A compounding pharmacy, to provide compounded GLP-1 formulations with rigorous quality controls and reliable fulfillment.
- 503A compliant
- Cold Sterile Injectables
- Dedicated Account Managers
- Free Provider portal
GLP-1 Injectable
Available for subcutaneous administration through your Evitalin provider portal
Why Providers Choose PharmaLabs
- Excellent tolerability profile
- Multiple concentration options
- Cold-chain shipped for stability
- Patient-specific compounding
- Bill Patient or Bill Clinic models
Ready to Watch the Full Presentation?
Get immediate access to this clinical deep dive on GLP-1 agonists and tirzepatide in practice.